In its third quarter ended October 30, 2025, Kimberly-Clark delivered adjusted earnings per share of $1.82, beating consensus estimates by $0.07, and reported revenue of $4.15 billion, surpassing expectations by $50 million. Organic sales grew 2.5% on a 2.4% volume increase, offsetting flat pricing and portfolio mix, while gross margin stood at 36.8%, down 170 basis points due to tariff-driven cost inflation. The company also confirmed a definitive agreement to acquire Kenvue for $48.7 billion in cash and stock, a transaction expected to bolster its consumer health portfolio and unlock significant synergies over the next three years.

Kimberly-Clark has increased its dividend for 53 straight years, maintaining its status among the elite Dividend Kings. The current annualized payout of $5.04 per share implies a yield of approximately 5.1%, more than four times the S&P 500 average. The company’s conservative payout ratio of 85% of trailing earnings underpins the sustainability of its distributions, even in the event of economic headwinds, reflecting strong free cash flow generation from core personal care and tissue operations across 175 markets.

During the third quarter, Allspring Global Investments trimmed its holdings in Kimberly-Clark by 49.1%, selling 21,259 shares and ending the period with 22,001 shares valued at $2.71 million. Meanwhile, Vanguard Group raised its stake by 14.8%, adding 5.2 million shares and holding over 40 million shares worth more than $5.2 billion, and Charles Schwab Investment Management increased its position by 1.9% to 11.48 million shares. Institutional ownership remains high at 76.3%, underscoring confidence among large asset managers despite recent portfolio reallocations.